TrialCancer2023

Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.

Kristina A Cole et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.